DSCSA for pharma 3PLs.
Under the Drug Supply Chain Security Act, a third-party logistics provider stores or moves prescription drugs without owning them, must be licensed and report that licence to FDA each year, and must support its clients' tracing and suspect-product duties.
DSCSA carved third-party logistics providers into their own category: entities that take custody of drugs without taking ownership. Licensure and reporting are the floor; the real test is operational — a 3PL sits inside its clients' data flows, and every serialization exception that happens in your building is a client relationship problem the same day.
DSCSA for 3PLs, in three facts.
US DSCSA · 3PLs recognized as a distinct licensed category · custody without ownership · data pass-through in force.
Third-party logistics providers that handle prescription drugs must be licensed and report their licensure to FDA every year.
Source: FDA, annual reporting by wholesale distributors and 3PLsThe DSCSA's enhanced drug distribution security requirements apply from 27 November 2023, and FDA's stabilization period ended on 27 November 2024.
Source: FDA, Drug Supply Chain Security ActFDA's DSCSA exemption for eligible wholesale distributors ended on 27 August 2025.
Source: FDA, exemptions under DSCSA
You don't own it. You still answer for it.
Licensure and reporting
3PLs are licensed (state or federal facility reporting) as their own category — operating unlicensed ends the pharma business line.
Custody integrity
Product in your custody must remain traceable: receipts, holds, ships, all reconcilable to the owner's serialized records at unit level.
Data pass-through without corruption
TI/TS flows between your clients and their partners through your operations — your WMS touching the flow must never orphan a serial.
Client-facing exception duty
When physical product and EPCIS data disagree on your dock, you are the first to know and contractually the first to answer.
The timeline, as it stands.
3PL duties are in force, and pharma clients now write serialization performance into logistics contracts — exception rates and verification turnaround are becoming commercial terms, not compliance footnotes.
Three moves that de-risk the deadline.
Reconcile custody at unit level
Daily reconciliation of physical inventory against clients' serialized records — sampling, not wall-to-wall counts — catches drift before clients do.
Instrument the dock
Receiving and shipping should verify serialized identity as product moves, writing events your clients' systems consume without manual touch.
Sell the capability
A 3PL that can prove clean custody at unit level wins pharma contracts on exactly that proof. Make the metric visible to prospects.
Custody you can show, not assert.
Aeroz gives 3PLs dock-speed verification: chip-read identity checks on receipt and dispatch, custody events appended to an EPCIS 2.0 log your clients can audit. Exceptions surface at the door instead of in a client's reconciliation, and 'we never lose a serial' becomes a claim with a log behind it.
DSCSA for 3PLs, answered.
Are 3PLs really a separate DSCSA category?
Yes — DSCSA defines third-party logistics providers as entities providing warehousing and distribution services without taking ownership, with their own licensure and reporting track.
Do 3PLs exchange transaction data?
The ownership-holding partners exchange TI/TS, but the data describes product physically moving through the 3PL — so the 3PL's operations must keep physical and data flows aligned, and many contracts route the data through 3PL systems.
What do pharma clients now demand of 3PLs?
Unit-level custody integrity, fast verification support during suspect-product events, and low exception rates — increasingly written into SLAs with penalties.
What changes for 3PLs in 2033?
The NDC-12 transition reformats the identifiers inside every barcode and record a 3PL touches; WMS parsing and client integrations all migrate, ideally years early.
Know exactly where you stand — in 14 days.
A fixed-fee Aeroz audit maps your products against DSCSA for 3PLs requirements and returns a written readiness assessment, a data-mapping review, and a scoped pilot plan with cost and timeline.